Tetraphase Pharmaceuticals, Inc. (TTPH) Expected to Announce Earnings of -$0.63 Per Share
Equities analysts expect Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) to post earnings per share of ($0.63) for the current fiscal quarter, according to Zacks Investment Research. Three analysts have provided estimates for Tetraphase Pharmaceuticals’ earnings, with the highest EPS estimate coming in at ($0.49) and the lowest estimate coming in at ($0.76). Tetraphase Pharmaceuticals posted earnings of ($0.58) per share during the same quarter last year, which would indicate a negative year-over-year growth rate of 8.6%. The firm is expected to report its next quarterly earnings results on Thursday, November 2nd.
According to Zacks, analysts expect that Tetraphase Pharmaceuticals will report full year earnings of ($2.77) per share for the current fiscal year, with EPS estimates ranging from ($2.97) to ($2.49). For the next year, analysts expect that the company will report earnings of ($1.94) per share, with EPS estimates ranging from ($2.75) to ($1.69). Zacks’ EPS averages are a mean average based on a survey of sell-side research firms that follow Tetraphase Pharmaceuticals.
Tetraphase Pharmaceuticals (NASDAQ:TTPH) last released its quarterly earnings results on Wednesday, August 2nd. The biopharmaceutical company reported ($0.83) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.76) by ($0.07). The company had revenue of $1.59 million for the quarter, compared to analyst estimates of $1.54 million. Tetraphase Pharmaceuticals had a negative net margin of 2,092.20% and a negative return on equity of 79.79%. Tetraphase Pharmaceuticals’s revenue for the quarter was up 28.2% on a year-over-year basis. During the same quarter last year, the firm posted ($0.47) EPS.
A number of brokerages have weighed in on TTPH. Needham & Company LLC restated a “hold” rating on shares of Tetraphase Pharmaceuticals in a report on Sunday, September 17th. Zacks Investment Research upgraded shares of Tetraphase Pharmaceuticals from a “hold” rating to a “buy” rating and set a $7.75 price objective on the stock in a report on Saturday, September 23rd. BidaskClub cut shares of Tetraphase Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Thursday, August 10th. HC Wainwright began coverage on shares of Tetraphase Pharmaceuticals in a report on Tuesday, July 11th. They issued a “buy” rating and a $15.00 price objective on the stock. Finally, Stifel Nicolaus restated a “buy” rating and issued a $13.00 price objective on shares of Tetraphase Pharmaceuticals in a report on Tuesday, September 12th. Two analysts have rated the stock with a sell rating, three have issued a hold rating and four have given a buy rating to the company. The company has an average rating of “Hold” and an average target price of $12.96.
Tetraphase Pharmaceuticals (TTPH) traded up 0.15% during trading on Wednesday, reaching $6.48. The company’s stock had a trading volume of 192,740 shares. The firm’s market cap is $330.82 million. The company has a 50-day moving average of $6.97 and a 200 day moving average of $7.24. Tetraphase Pharmaceuticals has a one year low of $3.11 and a one year high of $9.93.
In other news, insider Jacques Dumas sold 17,500 shares of the stock in a transaction that occurred on Tuesday, August 22nd. The shares were sold at an average price of $6.00, for a total transaction of $105,000.00. Following the sale, the insider now owns 17,500 shares in the company, valued at $105,000. The transaction was disclosed in a filing with the SEC, which is available at this link. Corporate insiders own 5.50% of the company’s stock.
Several large investors have recently bought and sold shares of TTPH. UBS Group AG boosted its holdings in Tetraphase Pharmaceuticals by 2.3% in the first quarter. UBS Group AG now owns 17,269 shares of the biopharmaceutical company’s stock worth $159,000 after purchasing an additional 387 shares during the last quarter. Schwab Charles Investment Management Inc. boosted its holdings in Tetraphase Pharmaceuticals by 0.7% in the second quarter. Schwab Charles Investment Management Inc. now owns 129,681 shares of the biopharmaceutical company’s stock worth $925,000 after purchasing an additional 874 shares during the last quarter. American International Group Inc. boosted its holdings in Tetraphase Pharmaceuticals by 7.1% in the first quarter. American International Group Inc. now owns 22,390 shares of the biopharmaceutical company’s stock worth $206,000 after purchasing an additional 1,486 shares during the last quarter. Citadel Advisors LLC boosted its holdings in Tetraphase Pharmaceuticals by 18.6% in the first quarter. Citadel Advisors LLC now owns 15,924 shares of the biopharmaceutical company’s stock worth $146,000 after purchasing an additional 2,496 shares during the last quarter. Finally, Rhumbline Advisers boosted its holdings in Tetraphase Pharmaceuticals by 5.7% in the second quarter. Rhumbline Advisers now owns 51,633 shares of the biopharmaceutical company’s stock worth $368,000 after purchasing an additional 2,780 shares during the last quarter. Hedge funds and other institutional investors own 41.73% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This article was first published by American Banking News and is the sole property of of American Banking News. If you are viewing this article on another domain, it was stolen and reposted in violation of United States & international copyright and trademark law. The original version of this article can be read at https://www.americanbankingnews.com/2017/10/18/tetraphase-pharmaceuticals-inc-ttph-expected-to-announce-earnings-of-0-63-per-share.html.
About Tetraphase Pharmaceuticals
Tetraphase Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. The Company is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections, including multidrug-resistant gram-negative infections.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Tetraphase Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.